Systems Biology Opens New Research Pathways
Systems Biologists Are Attacking the Encrypted Messages That Would Allow Us to Predict and Change the Course of Disease
Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
Biopharma M&As in 2012
The past few years have certainly gotten the biotech industry used to seeing multiple acquisition deals well over $1 billion, particularly among drug developers. While M&A activity was strong in 2011, the number of those huge blockbuster agreements seems to be lower. Sanofi came in at number 1 with its $20.1 billion buy of Genzyme—about half of the $41 billion that last year’s top-spender, Novartis, paid for Alcon. The top-five list for 2011 ends with Forest Laboratories’ $1.2 billion purchase of Clinical Data, while last year the fifth place went to Daiichi Sankyo when it bought Ranbaxy for $4.6 billion. Do you expect mega mergers to return in full force next year? What’s your forecast for M&A activity among biopharmaceutical companies for 2012?